Schizophrenia
Conditions
Keywords
memantine, adjunctive therapy, schizophrenia
Brief summary
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized that adjunctive therapy with memantine will reduce NMDA receptor hyperactivity, improving signal to noise ratio and thereby improving cognitive symptoms.
Interventions
DRUGmemantine HCl
Sponsors
Forest Laboratories
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* DSM-IV diagnosed Schizophrenia or schizoaffective disorder who are on a stable antipsychotic regimen with Brief Psychiatric Rating Scale (BPRS) total score greater than or equal to 26 and greater than or equal to 4 on at least one item
Exclusion criteria
* Secondary diagnosis of Bipolar I disorder * Suicidal history * Organic brain disease * Dementia * History of substance abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Symptom Scale (PANSS) - Total Score | — |
Secondary
| Measure | Time frame |
|---|---|
| PANNS - Positive Score | — |
| PANSS - Negative Score | — |
| Clinical Global Impression - Severity (CGI-S) | — |
| Brief Assessment of Cognition | — |
| Clinical Global Impression - Improvement | — |
| Calgary Depression Scale for Schizophrenia | — |
Countries
United States
Outcome results
None listed